Search > Results
You searched for: EV210106 (EV-TRACK ID)
Showing 1 - 5 of 5
Showing 1 - 5 of 5
Details | EV-TRACK ID | Experiment nr. | Species | Sample type | Separation protocol | First author | Year | EV-METRIC |
---|---|---|---|---|---|---|---|---|
EV210106 | 5/5 | Homo sapiens | Urine |
(d)(U)C Filtration |
Andreu, Zoraida | 2016 | 33% | |
Study summaryFull title
All authors
Zoraida Andreu, Renan Otta Oshiro, Alberto Redruello, Soraya López-Martín, Cristina Gutiérrez-Vázquez, Esperanza Morato, Ana Isabel Marina, Carlos Olivier Gómez, María Yáñez-Mó
Journal
Eur J Pharm Sci.
Abstract
Bladder cancer is the second most frequent malignancy of the urinary tract after prostate cancer. Cu (show more...)
EV-METRIC
33% (65th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Urine
Sample origin
Bladder cancer
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(d)(U)C
Filtration Protein markers
EV: Filamin-A/ ApoE/ ApoB/ CD9/ ERM
non-EV: None Proteomics
yes
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Urine
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: time(min)
60
Pelleting: rotor type
JS-24.38
Pelleting: speed (g)
100000
Wash: volume per pellet (ml)
33
Wash: time (min)
60
Wash: Rotor Type
JS-24.38
Wash: speed (g)
100000
Filtration steps
0.22µm or 0.2µm
Characterization: Protein analysis
Protein Concentration Method
Not determined
Western Blot
Antibody details provided?
No
Detected EV-associated proteins
ERM/ ApoB/ CD9
Proteomics database
No
Detected EV-associated proteins
Filamin-A/ ApoE/ ApoB
Characterization: RNA analysis
RNA analysis
Type
(RT)(q)PCR
Database
No
Proteinase treatment
No
RNAse treatment
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
130
EM
EM-type
Transmission-EM
Image type
Wide-field
|
||||||||
EV210106 | 1/5 | Homo sapiens | J82 |
(d)(U)C Filtration |
Andreu, Zoraida | 2016 | 29% | |
Study summaryFull title
All authors
Zoraida Andreu, Renan Otta Oshiro, Alberto Redruello, Soraya López-Martín, Cristina Gutiérrez-Vázquez, Esperanza Morato, Ana Isabel Marina, Carlos Olivier Gómez, María Yáñez-Mó
Journal
Eur J Pharm Sci.
Abstract
Bladder cancer is the second most frequent malignancy of the urinary tract after prostate cancer. Cu (show more...)
EV-METRIC
29% (68th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Cell culture supernatant
Sample origin
Control condition
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(d)(U)C
Filtration Protein markers
EV: None
non-EV: None Proteomics
yes
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Cell culture supernatant
EV-producing cells
J82
EV-harvesting Medium
EV-depleted medium
Preparation of EDS
Not specified
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: time(min)
60
Pelleting: rotor type
JS-24.38
Pelleting: speed (g)
100000
Wash: volume per pellet (ml)
33
Wash: time (min)
60
Wash: Rotor Type
JS-24.38
Wash: speed (g)
100000
Filtration steps
0.22µm or 0.2µm
Characterization: Protein analysis
Protein Concentration Method
Not determined
Proteomics database
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
None
|
||||||||
EV210106 | 2/5 | Homo sapiens | UMUC-3 |
(d)(U)C Filtration |
Andreu, Zoraida | 2016 | 29% | |
Study summaryFull title
All authors
Zoraida Andreu, Renan Otta Oshiro, Alberto Redruello, Soraya López-Martín, Cristina Gutiérrez-Vázquez, Esperanza Morato, Ana Isabel Marina, Carlos Olivier Gómez, María Yáñez-Mó
Journal
Eur J Pharm Sci.
Abstract
Bladder cancer is the second most frequent malignancy of the urinary tract after prostate cancer. Cu (show more...)
EV-METRIC
29% (68th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Cell culture supernatant
Sample origin
Control condition
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(d)(U)C
Filtration Protein markers
EV: None
non-EV: None Proteomics
yes
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Cell culture supernatant
EV-producing cells
UMUC-3
EV-harvesting Medium
EV-depleted medium
Preparation of EDS
Not specified
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: time(min)
60
Pelleting: rotor type
JS-24.38
Pelleting: speed (g)
100000
Wash: volume per pellet (ml)
33
Wash: time (min)
60
Wash: Rotor Type
JS-24.38
Wash: speed (g)
100000
Filtration steps
0.22µm or 0.2µm
Characterization: Protein analysis
Protein Concentration Method
Not determined
Proteomics database
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
None
|
||||||||
EV210106 | 3/5 | Homo sapiens | SW780 |
(d)(U)C Filtration |
Andreu, Zoraida | 2016 | 29% | |
Study summaryFull title
All authors
Zoraida Andreu, Renan Otta Oshiro, Alberto Redruello, Soraya López-Martín, Cristina Gutiérrez-Vázquez, Esperanza Morato, Ana Isabel Marina, Carlos Olivier Gómez, María Yáñez-Mó
Journal
Eur J Pharm Sci.
Abstract
Bladder cancer is the second most frequent malignancy of the urinary tract after prostate cancer. Cu (show more...)
EV-METRIC
29% (68th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Cell culture supernatant
Sample origin
Control condition
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(d)(U)C
Filtration Protein markers
EV: None
non-EV: None Proteomics
yes
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Cell culture supernatant
EV-producing cells
SW780
EV-harvesting Medium
EV-depleted medium
Preparation of EDS
Not specified
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: time(min)
60
Pelleting: rotor type
JS-24.38
Pelleting: speed (g)
100000
Wash: volume per pellet (ml)
33
Wash: time (min)
60
Wash: Rotor Type
JS-24.38
Wash: speed (g)
100000
Filtration steps
0.22µm or 0.2µm
Characterization: Protein analysis
Protein Concentration Method
Not determined
Proteomics database
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
None
|
||||||||
EV210106 | 4/5 | Homo sapiens | Urine |
(d)(U)C Filtration |
Andreu, Zoraida | 2016 | 22% | |
Study summaryFull title
All authors
Zoraida Andreu, Renan Otta Oshiro, Alberto Redruello, Soraya López-Martín, Cristina Gutiérrez-Vázquez, Esperanza Morato, Ana Isabel Marina, Carlos Olivier Gómez, María Yáñez-Mó
Journal
Eur J Pharm Sci.
Abstract
Bladder cancer is the second most frequent malignancy of the urinary tract after prostate cancer. Cu (show more...)
EV-METRIC
22% (49th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Urine
Sample origin
Control condition
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(d)(U)C
Filtration Protein markers
EV: Filamin-A/ ApoE/ ApoB/ CD9/ ERM
non-EV: None Proteomics
yes
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Urine
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: time(min)
60
Pelleting: rotor type
JS-24.38
Pelleting: speed (g)
100000
Wash: volume per pellet (ml)
33
Wash: time (min)
60
Wash: Rotor Type
JS-24.38
Wash: speed (g)
100000
Filtration steps
0.22µm or 0.2µm
Characterization: Protein analysis
Protein Concentration Method
Not determined
Western Blot
Antibody details provided?
No
Detected EV-associated proteins
ERM/ CD9
Not detected EV-associated proteins
ApoB
Proteomics database
No
Detected EV-associated proteins
Filamin-A/ ApoE/ ApoB
Characterization: RNA analysis
RNA analysis
Type
(RT)(q)PCR
Database
No
Proteinase treatment
No
RNAse treatment
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
None
|
||||||||
1 - 5 of 5 |
EV-TRACK ID | EV210106 | ||||
---|---|---|---|---|---|
species | Homo sapiens | ||||
sample type | Urine | Cell culture | Cell culture | Cell culture | Urine |
cell type | NA | J82 | UMUC-3 | SW780 | NA |
medium | NA | EV-depleted medium | EV-depleted medium | EV-depleted medium | NA |
condition | Bladder cancer | Control condition | Control condition | Control condition | Control condition |
separation protocol | (d)(U)C Filtration | (d)(U)C Filtration | (d)(U)C Filtration | (d)(U)C Filtration | (d)(U)C Filtration |
Exp. nr. | 5 | 1 | 2 | 3 | 4 |
EV-METRIC % | 33 | 29 | 29 | 29 | 22 |